Literature DB >> 11814559

Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh.

Ole Isacson1, Hyemyung Seo, Ling Lin, David Albeck, Ann Charlotte Granholm.   

Abstract

Recent therapeutic investigations of Alzheimer's disease (AD) have been guided by two seemingly opposed hypotheses: the amyloid cascade theory, which favors the amyloid plaques as the cause of AD; and the cholinergic theory, which favors cholinergic neuron loss as the cause. New investigations indicate that the synthesis and processing of the amyloid precursor protein (APP) is linked to the trophic actions of nerve growth factor. A pathological cascade in both AD- and Down's syndrome-related memory loss could be triggered by alterations in APP processing or ACh-mediated neuronal function, or both, which in turn trigger the overexpression of amyloid beta, synaptic malfunction and trophic factor loss in target regions. This eventually leads to synaptic and dendritic loss with age.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11814559     DOI: 10.1016/s0166-2236(02)02037-4

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  55 in total

1.  Bidirectional modulation of visual plasticity by cholinergic receptor subtypes in the frog optic tectum.

Authors:  Chuan-Jiang Yu; Christopher M Butt; Elizabeth A Debski
Journal:  Eur J Neurosci       Date:  2003-03       Impact factor: 3.386

Review 2.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

3.  Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study.

Authors:  Alexander P Lin; Frederick Shic; Cathleen Enriquez; Brian D Ross
Journal:  MAGMA       Date:  2003-02       Impact factor: 2.310

4.  Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome.

Authors:  Jisook Moon; May Chen; Shruti U Gandhy; Myla Strawderman; David A Levitsky; Kenneth N Maclean; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2010-06       Impact factor: 1.912

Review 5.  Deconstructing signal transduction pathways that regulate the actin cytoskeleton in dendritic spines.

Authors:  Peter Penzes; Michael E Cahill
Journal:  Cytoskeleton (Hoboken)       Date:  2012-03-12

6.  A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Hiroaki Fukumoto; Hideki Takahashi; Naoki Tarui; Junji Matsui; Taisuke Tomita; Mitsuhiro Hirode; Masumi Sagayama; Ryouta Maeda; Makiko Kawamoto; Kazuko Hirai; Jun Terauchi; Yasufumi Sakura; Mitsuru Kakihana; Kaneyoshi Kato; Takeshi Iwatsubo; Masaomi Miyamoto
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

7.  The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective.

Authors:  Ahmad Salehi; J Wesson Ashford; Elliott J Mufson
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

8.  Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Authors:  Brian E Powers; Ramon Velazquez; Christy M Kelley; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Brain Struct Funct       Date:  2015-12-30       Impact factor: 3.270

9.  Age-dependent loss of NGF signaling in the rat basal forebrain is due to disrupted MAPK activation.

Authors:  Brice Williams; Ann-Charlotte Granholm; Kumar Sambamurti
Journal:  Neurosci Lett       Date:  2006-12-19       Impact factor: 3.046

10.  The increase of choline acetyltransferase activity by docosahexaenoic acid in NG108-15 cells grown in serum-free medium is independent of its effect on cell growth.

Authors:  Eva Machová; Barbora Málková; Vera Lisá; Jana Nováková; Vladimír Dolezal
Journal:  Neurochem Res       Date:  2006-10       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.